Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2023-03-17 00:00:00 ET · period of report 2023-03-15 · accession 0001209191-23-019880 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-17 | 2023-03-15 | TARS | Trevejo Jose M. | Chief Medical Off | M - OptEx | — | +7,549 | 9,153 | +471% | — |
| D | 2023-03-17 | 2023-03-16 | TARS | Trevejo Jose M. | Chief Medical Off | S - Sale+OE | $13.43 | -499 | 8,654 | -5% | -$6,702 |
| D | 2023-03-17 | 2023-03-15 | TARS | Trevejo Jose M. | Chief Medical Off | M - OptEx | $0.00 | -7,549 | 22.6K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-15 | M | A | 7,549 | — | 9,153 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). (F2) includes 1,604 shares acquired under the Issuer's employee stock purchase plan on December 31, 2022. |
| 2 | Common | Common Stock | 2023-03-16 | S | D | 499 | $13.43 | 8,654 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2023-03-15 | M | D | 7,549 | $0.00 | 22,648 | D | — · — to — | 7,549 Common Stock | (F4) Each RSU represents a contingent right to receive one share of the Company's common stock. (F5) RSU granted on February 1, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. |